Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medrysone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.93 |
| ▸ | LMNA | P02545 | 5/20 | 0.93 |
| ▸ | PGR | P06401 | 2/20 | 0.93 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.66 |
| ▸ | HSD11B2 | P80365 | 4/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.65 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | SHBG | P04278 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.57 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medrysone SCHEMBL12998543 | 0.96 | CYP3A4 (1.00) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| Medrysone SCHEMBL4493 | 0.96 | CYP3A4 (1.00) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| Medrysone SCHEMBL29866793 | 0.96 | CYP3A4 (1.00) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| Medrysone SCHEMBL13054978 | 0.96 | CYP3A4 (1.00) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| Medrysone SCHEMBL3048275 | 0.96 | CYP3A4 (1.00) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| SCHEMBL8668298 | 0.90 | SMN1; SMN2 (0.80) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| SCHEMBL8668291 | 0.90 | SMN1; SMN2 (0.80) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| SCHEMBL23975165 | 0.88 | CYP3A4 (0.85) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| Medrysone SCHEMBL19327153 | 0.84 | CYP3A4 (0.71) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA | |
| SCHEMBL6018287 | 0.84 | CYP3A4 (0.77) | CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276420-A2 | THERAPEUTIC DEVICE FOR PAIN MANAGEMENT AND VISION | Forsight Labs, Llc (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009145842-A9 | THERAPEUTIC DEVICE FOR PAIN MANAGEMENT AND VISION | FORSIGHT LABS, LLC (US) | 2010-11-18 | — | — | WO | claimed |
| WO-2009145842-A2 | THERAPEUTIC DEVICE FOR PAIN MANAGEMENT AND VISION | FORSIGHT LABS, LLC (US) | 2009-12-03 | — | — | WO | claimed |
| EP-1740168-A2 | ANTIPROSTAGLANDINS FOR THE TREATMENT OF OCULAR PATHOLOGIES | Advanced Ocular Systems Limited (AU) | 2007-01-10 | — | — | EP | claimed |
| EP-1720555-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF OCULAR PATHOLOGIES | Advanced Ocular Systems Limited (AU) | 2006-11-15 | — | — | EP | claimed |
| EP-1718314-A1 | HEPARIN FOR THE TREATMENT OF OCULAR PATHOLOGIES | Advanced Ocular Systems Limited (AU) | 2006-11-08 | — | — | EP | claimed |
| US-20060122152-A1 | Heparin for the treatment of ocular pathologies | MINU, LLC | 2006-06-08 | — | — | US | claimed |
| US-20050261243-A1 | Antiprostaglandins for the treatment of ocular pathologies | MINU, LLC | 2005-11-24 | — | — | US | claimed |
| US-20050256081-A1 | Tetracycline derivatives for the treatment of ocular pathologies | MINU, LLC | 2005-11-17 | — | — | US | claimed |
| WO-2005102303-A2 | ANTIPROSTAGLANDINS FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-11-03 | — | — | WO | claimed |
| WO-2005082376-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | claimed |
| WO-2005082380-A1 | HEPARIN FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | claimed |
| US-20240122879-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-18 | — | — | US | disclosed |
| WO-2023154980-A1 | TREATMENT OF ANATOMICAL AND FUNCTIONAL RETINAL ATROPHIES | EYE CO PTY LTD (AU) | 2023-08-24 | — | — | WO | disclosed |
| EP-2276420-B1 | DEVICE TO TREAT AN EYE HAVING AN EPITHELIUM WITH A DEFECT | JOURNEY1 INC (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-2753395-B1 | METHOD AND DEVICE FOR DELIVERY OF SUBSTANCES | INTERNATIONAL SCIENT PTY LTD (AU) | 2020-07-29 | — | — | EP | disclosed |
| WO-2005102303-A2 | ANTIPROSTAGLANDINS FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005099715-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD. (AU) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005082376-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082380-A1 | HEPARIN FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122879-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS | GSDMD, CRYAB, CASP1 | NR3C1 2478/4885CYP3A4 2394/4885HIF1A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.